The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients

Transfusion

Volumn 53, Issue 10, 2013, Pages 2183-2189

  Ziemann, Malte ^a   Juhl, David ^a   Görg, Siegfried ^a   Hennig, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CONCENTRATION (PARAMETERS); CYTOMEGALOVIRUS INFECTION; DNA CONTENT; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; PLASMA; PRACTICE GUIDELINE; RISK ASSESSMENT; VIREMIA; VIRUS DETECTION;

BLOOD DONORS; BLOOD TRANSFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; RISK;

EID: 84885834850     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12199     Document Type: Article

References (19)

1. Klemola E, Kaariainen L,. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br Med J 1965; 2: 1099-1102.
2. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG,. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98: 281-287. (Pubitemid 11191091)
3. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W,. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-3603.
4. Söderberg-Naucler C, Fish KN, Nelson JA,. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus- permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997; 100: 3154-3163. (Pubitemid 28022854)
5. Vamvakas EC,. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005; 19: 181-199. (Pubitemid 40943570)
6. Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H,. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972-1983. (Pubitemid 47623966)
7. Dumont LJ, Luka J, VandenBroeke T, Whitley P, Ambruso DR, Elfath MD,. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 2001; 97: 3640-3647.
8. Drew WL, Roback JD,. Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion 2007; 47: 1955-1958. (Pubitemid 47623987)
9. Ziemann M, Heuft HG, Frank K, Kraas S, Görg S, Hennig H,. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 2013. doi: 10.1111/trf.12074.
10. Söderberg-Naucler C, Fish KN, Nelson JA,. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-126. (Pubitemid 27431318)
11. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF,. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol 2006; 35: 338-342. (Pubitemid 43188985)
12. Ziemann M, Unmack A, Steppat D, Juhl D, Görg S, Hennig H,. The natural course of primary cytomegalovirus infection in blood donors. Vox Sang 2010; 99: 24-33.
13. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF,. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999; 180: 702-707. (Pubitemid 29411355)
14. Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L, Gerna G,. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998; 177: 1170-1175. (Pubitemid 28194253)
15. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD,. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036. (Pubitemid 30339241)
16. Kotton CN, Kumar D, Caliendo AM, Åsberg A, Chou S, Snydman DR, Allen U, Humar A,; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
17. Thiele T, Krüger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, Dölken G, Greinacher A,. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51: 2620-2626.
18. Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang JH, Champion M, Fang C, Dodd R,. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010; 50: 776-786.
19. Josephson CD, Castillejo MI, Caliendo AM, Waller EK, Zimring J, Easley KA, Kutner M, Hillyer CD, Roback JD,. Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions. Transfus Med Rev 2011; 25: 125-132.